The drug is certainly safe and it is not total ineffective or else it would not have passed this analysis. What we don’t know is how effective it is and we won’t know this for some time. All biotech is a bit of a gamble, but at the current SP I think the risk/reward ratio is still in our favour.
Ann: Dimerix Successfully Passes Efficacy Interim Analysis, page-147
- There are more pages in this discussion • 133 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add DXB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
64.5¢ |
Change
0.065(11.2%) |
Mkt cap ! $354.5M | |||
| Open | High | Low | Value | Volume |
| 59.0¢ | 65.0¢ | 58.0¢ | $3.696M | 5.951M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 100000 | 64.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 65.0¢ | 109360 | 4 |
View Market Depth
| Last trade - 16.10pm 14/06/2024 (20 minute delay) ? |
|
|||||
|
Last
64.5¢ |
Change
0.065 ( 12.4 %) |
||||
| Open | High | Low | Volume | ||
| 59.0¢ | 65.5¢ | 58.5¢ | 3782284 | ||
| Last updated 15.59pm 14/06/2024 ? | |||||
| DXB (ASX) Chart |